Ocular Therapeut OCUL

$6.47 -0.03 (-0.46%)

Valuation

Market cap
1,427,504,000
Revenue TTM
$51,950,000
Net income TTM
$-265,940,000
PE ratio
0.00
Forward PE
—
Profit margin
-511.92%
Debt to equity
0.14

Trading

Volume
1,690,400
Avg volume
3,269,034
Day's range
$6.40 – $6.62
Shares out
219,616,000
Stochastic %K
32%
Beta
1.00
Analysts
Strong Sell
Price target
$25.67

Price

Company profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunc...

Show more

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 357 4000
Website
https://www.ocutx.com
Address
14 Crosby Drive, 3rd Floor, Bedford, United States

Latest news

Stocktwits

LoneBroker Oct 27, 1:23 AM
$OCUL $VELO $QBTS
0 replies
nicky7 Oct 27, 1:14 AM
$OCUL not what my crystal ball was telling me
0 replies
MaxKlim Oct 26, 8:46 PM
$OCUL https://www.nasdaq.com/market-activity/stocks/ocul/short-interest
1 replies
WarrenDouglasTrader Oct 26, 8:13 PM
$OCUL This turned into a steaming pile. Zero buyers. Street not buying Dugel story at all. Why?
4 replies
Jugglerio Oct 26, 8:09 PM
$OCUL need something to ignite this trash pile
2 replies
Merlintrader Oct 26, 7:09 PM
$OCUL Premium report (free with an ad), now with a downloadable 20-page PDF. Ocular plans the AXPAXLI NDA submission in Q4 2026, reaffirmed on Sep 15; SOL-1 ran under an FDA SPA. Cash was USD 598.6M at June 30, with USD 82.5M of Barings debt due Aug 2029. Shares closed at USD 6.50 on Oct 23. Full hub (NDA path, SOL-1 and SOL-R, cash, dilution): https://www.merlintrader.com/ocular-therapeuthix-stock-hu/ Not investment advice.
0 replies
WarrenDouglasTrader Oct 26, 6:28 PM
$OCUL Man this stock sucks
0 replies
BirdWithBigBalls Oct 26, 2:39 PM
$OCUL everyone wants to be a ceo until it's time to do what ceos actually do.
1 replies